












doi:10.101Bone Mineral Density after Bone Marrow
Transplantation in Childhood: Measurement
and Associations
Kathy Ruble,1 Matthew J. Hayat,2 Kerry J. Stewart,3 Allen R. Chen1This study examined the bone mineral density (BMD) of 46 (median age 16.3, 8-29) survivors of autologous
and allogeneic bone marrow transplantation (BMT). Areal (g/m2) BMD was acquired with dual energy x-ray
absorptiometry and volumetric (g/cm3) BMD values were calculated. Abnormal BMD was identified in 24%
(11/46) of survivors with areal measures and 22% (10/46) with volumetric measures. Comparison of areal
and volumetric BMD revealed the measures were highly correlated (r5 0.73, p\0.001) but clinical diagnosis
of osteopenia/osteoporosis were not consistent. Volumetric z-scores were higher for 7/8 of the survivors
who were\ 3rd percentile for height. Associations of BMD and body composition and disease and treat-
ment factors were assessed with multiple linear regression. When controlling for other significant associa-
tions and cumulative steroid dose, the body composition measure of fat mass index (FMI) was associated
with higher volumetric BMD z-scores (CI: 0.006, 0.193; p 5 0.037). CNS irradiation (CI: -1.710,-0.200;
p 5 0.015), age at time of testing (CI: -0.116, -0.024; p 5 0.004) and female sex (CI: -1.375, -0.155; p 5
0.015) were associated with lower volumetric BMD z-scores. Conclusions: Childhood BMT survivors are
at risk for diminished BMD. Areal and volumetric DEXA derived measures of BMD are highly correlated
and volumetric measures may correct for underestimation of BMD in BMT survivors who are small for
age. Survivors who received CNS irradiation, are older and female may be at greater risk for diminished
BMD while fat mass is associated with higher BMD in childhood BMT survivors.
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Diminished bonemineral density (BMD) is a known
complication after bonemarrow transplantation (BMT)
in children [1-3]. Endocrine dysfunction, irradiation,
corticosteroids, and chronic graft versus host disease
(cGVHD) have been identified as risk factors for
diminished BMD in childhood cancer survivors [4-9].
Our understanding of the mechanisms and risks for
diminished BMD after childhood BMT remains
incomplete, however.
Measurement of BMDdensity in childhood cancer
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for the clinical diagnosis of osteopenia/osteoporosis
based on z-scores calculated from age-, sex-, and
race-matched reference data. Many childhood BMT
survivors are small for their age, making the standard
z-score comparisons based on age and sex alone inac-
curate, leading to systematic underestimation of
BMD in smaller children [10]. Current recommenda-
tions call for the use of 3-dimensional (volumetric)
measurements of BMD in this population [11].
Dual-energy x-ray absorptiometry (DEXA) is the
most frequently used technique to assess BMD.
DEXA is readily available and associated with very
low exposure to ionizing radiation. It acquires BMD
measurements in 2 dimensions, with calculations
required to obtain volumetric measurements [12].
We were unable to identify any previous studies com-
paring areal and calculated volumetric BMDmeasure-
ments fromDEXA scans in childhood BMT survivors.
Maintenance of appropriate BMD is multifacto-
rial, influenced by other components of body compo-
sition, fat mass, and fat-free mass. The associations
between BMD and fat mass and fat-free mass vary
according to the population studied, but might explain
up to 31% of the variance in BMD seen in healthy1451
1452 Biol Blood Marrow Transplant 16:1451-1457, 2010K. Ruble et al.populations [13]. We identified no previous studies
examining the associations between BMD and body
composition in childhood BMT survivors. Knowledge
of these associations might be important to improving
our understanding of BMD outcomes and possibly
guiding treatment decisions.
The aims of the present study were to evaluate the
lumbar spine BMD of BMT survivors, compare the
DEXA scan acquired areal and volumetric measure-
ments of BMD, explore the relationship between
BMDmeasurements and body composition, and iden-
tify disease and treatment factors that predict dimin-
ished BMD.SUBJECTS AND METHODS
Subjects
Childhood BMT survivors who were at least 2
years posttransplantation were recruited from an
established survivor clinic, and recruitment letters
were mailed to those whose names and addresses
were generated from the institutional BMT database.
Twelve survivors were recruited from 160 mailings;
the remaining 34 were recruited from clinic visits.
This protocol was approved by the Johns Hopkins
Institutional Review Board, and informed consent
was obtained for all participants. Parental consent
and subject assent was obtained for those under the
age of 18 years.
Variables Analyzed
A medical records review was used to gather data
on age at time of BMT, years since BMT, autologous
versus allogeneic BMT, preparative regimen including
total body irradiation (TBI) or central nervous system
(CNS) irradiation (not just TBI), and history of
cGVHD. In addition, medical records were reviewed
to determine prednisone equivalent cumulative steroid
dose, including pretransplantation regimens until
resolution of cGVHD. Patient/family reports and
medical record reviews were used to assess endocrine
function, which was categorized as 1 (normal, no endo-
crinopathies or thyroid-stimulating hormone suppres-
sion therapy only) or 2 (abnormal, growth hormone
and/or gonadal hormone replacement). Physical
examination determined pubertal development by
Tanner stage (pubic hair). Height was measured to
the nearest centimeter with a stadiometer. Kilograms
of fat-free mass and fat mass were obtained from
DEXA data and were converted to fat mass index
(FMI) and fat-free mass index (FFMI) values using
the following formula: weight (kg)/height (m2).
BMD Measurement
BMD of the lumbar spine (L1-L4) was determined
by DEXA (Prodigy; GEHealthcare, Buckinghamshire,UK), which provided areal BMD (g/cm2) and age/sex/
ethnic matched z-scores derived from U.S. Food and
Drug Administration approved healthy controls. Volu-
metric BMD (g/cm3) values for L1-L4 were calculated
to determine the apparent BMDusing the formula: vol-
umetricBMD5BMD(4/(pwidth)) [14]. Volumetric
BMD z-scores were calculated from published lumbar
spine volumetric BMD (g/cm3) reference data on 444
age- and sex-matched healthy controls obtained using
the sameDEXAequipment and calculatedwith the fore-
going formula [15]. The z-scores from each
measurement were used to identify survivors meeting
WHO criteria for osteopenia (z 5 -1 to -2.5) and
osteoporosis (z\-2.5) [16].
Data Analysis
Stata 10 (StataCorp, College Station, TX) was
used for all analyses. The z-scores for areal (g/cm2)
and volumetric (g/cm3) BMDmeasurements were cal-
culated as described earlier and compared with WHO
criteria for osteopenia and osteoporosis. Pearson’s cor-
relation was used to examine the relationships between
areal and volumetric BMD measurements.
Univariate and multivariate analysis for volumetric
z-scores and predictor variables were performed. Mul-
tivariate model selection was performed with forward
selection. Covariates considered for the regression
model included age, age at time of BMT, years after
BMT, Tanner stage, endocrine function, CNS irradi-
ation, TBI, type of BMT, cGVHD, cumulative steroid
dose, FMI, and FFMI [4-6]. Significance was set at
a 5 .05.RESULTS
Subjects
Characteristics of the study subjects are summa-
rized in Table 1. The distribution of indications for
transplantation and transplant types were reasonably
representative of the distributions at the pediatric
BMT program at Johns Hopkins. In addition, approx-
imately 25% of the BMTs performed at Johns
Hopkins are done for nonmalignant diseases. In this
study, only 8 survivors had a nonmalignant condition,
including aplastic anemia and X-linked autoimmune/
allergic dysregulation syndrome, but no survivor had
thalassemia. Three of the survivors who received
CNS irradiation for a hematologic malignancy also
had a preparative regimen including TBI. Tanner
stages were bimodal and appropriately reflective of age.
BMD Measurement
BMD outcomes for BMT survivors were analyzed
using z-scores for areal and volumetric measures.
Using areal lumbar BMD z-scores, 22% (10/46) of

























Figure 1. Correlation of areal and volumetric lumbar spine BMD z-
scores. The open circles indicate subjects under the 3rd percentile for
height according to CDC growth charts.
Table 1. Subject Characteristics (n 5 46)
Age at time of testing, years, median
(range)
16.3 (8-29)
Age at BMT, years, median (range) 8 (0-21)
Years since BMT, median (range) 8 (2-22)
Males, n (%)






Allogeneic BMT, n (%) 30 (65%)
TBI-based preparative regimen, n (%) 15 (33%)
CNS irradiation, n (%) 8 (17%)
History of cGVHD, n (%) 8 (17%)
Abnormal endocrine function, n (%) 15 (30%)
Cumulative steroid dose, mg/m2 533 (0-68,517)
Fat-free mass index, kg/m2, mean ± SD 13.8 ± 2.2
Fat mass index, kg/m2, mean ± SD 6.0 ± 3.3
BMT indicates bone marrow transplantation; TBI, total body irradiation;
cGVHD, chronic graft-versus-host disease. Subjects were recruited
over an 18-month period from an established survivor program with ap-
proximately 630 participants, of whom approximately 200 have under-
gone BMT.
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bar spine BMD z-scores, 22% of the survivors (10/46)
met the criteria for osteopenia, and none met the crite-
ria for osteoporosis. Characteristics of survivors with
diminished volumetric BMD are presented in Table 3.
The comparison of areal and volumetric measures
included an analysis of values for survivors who were
small for their age and differences in WHO diagnoses
for the 2 measurements. As expected, areal lumbar and
volumetric lumbar BMD z-scores were correlated (r5
0.73; P\.001). For the 8 survivors who were below the
3rd percentile for height (according to Centers for
Disease Control and Prevention [CDC] growth
charts), 7 had higher z-scores with the volumetric
measurements. The only survivor who met the criteria
for osteoporosis had an areal z-score of -3.7 and a vol-
umetric z-score of -2.25. This survivor was an 18-year-
old male with a height of 153 cm (well below the 3rd
percentile).
Differences in classification of osteopenia/osteo-
porosis between the 2 measurements were identified
(Figure 1). Four of the 11 (36%) survivors with osteo-
penia identified using arealmeasurements had a normal
volumetric z-score, and this group had a median
height z-score of -1.37 (INTERQUARTILERANGE
1.27), calculated from National Health and Nutrition
Examination Survey (NHANES) data [18]. Three of
the 10 (30%) survivors with osteopenia identified using
volumetric measurements had a normal areal z-score,
and the median height z-score for this group was 0.39
(iqr 1.5).Regression Analysis
As supported by our data, volumetricmeasurement
is the recommended method for evaluating BMD inchildhood cancer survivors, and thus is the method
used for the predictive models. On univariate analysis,
only age (95% confidence interval [CI], -0.127 to
0.022; P 5 .007) and CNS irradiation (95% CI,
-1.870 to -0.089; P 5 .032) had statistically significant
associations with volumetric z-scores. Multiple linear
regression was performed with volumetric z-scores as
the response variable (Table 2). Controlling for cumu-
lative steroid dose, CNS irradiation, female sex, and
older age at the time of testing were significantly
associated with lower volumetric z-scores. FMI was
positively associated with volumetric z-scores.DISCUSSION
This study has identified several novel findings rel-
evant to the detection of and risk factors for diminished
BMD in survivors of BMT during childhood. First,
volumetric measurement appears to be the most
appropriate way to evaluate survivors who are small
for their age. Second, CNS irradiation, older age at
time of testing, and female sex are risk factors for di-
minished BMD. Third, we found a positive association
between FMI and BMD that has not been described in
previous studies of childhood BMT survivors.
BMD Measurement
The appropriate measurement of BMD in BMT
survivors is an important topic that remains under de-
bate. Although the use of volumetric measurement of
BMD has been recommended, the most suitable
examination technique has not yet been identified.
The most frequently used radiologic techniques for
measuring volumetric BMD are quantitative com-
puted tomography (QCT) and DEXA. Although
QCT provides a direct measurement of volumetric
BMD, it is associated with higher doses of ionizing










Neuroblastoma 21.26 Female 9 5 2 2 0
CNS tumor 22.25 Male 19 7 2 + 181
ALL 22.25 Female 27 16 + + 10,183
CNS tumor 21.71 Male 10 2 2 + 183
ALL 21.59 Female 20 2 + 2 5139
Rhabdomyocarcoma 21.43 Male 19 17 2 + 24
Wilms’ tumor 21.26 Female 23 5 2 + 0
AML 21.18 Female 25 19 2 2 6740
Aplastic anemia 21.13 Female 13 4 2 2 0
AML 21.10 Male 26 4 2 2 0
BMD indicates bone mineral density; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia.
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Although DEXA is considered the gold standard for
measuring BMD with minimal ionizing radiation, it
requires manual calculation [10]. Identifying the safest
and most accurate approach to measuring BMD after
BMT is important to both clinical practice and future
research.
In this study, the prevalence of diminished BMD
(osteopenia/osteoporosis) was similar regardless of
whether areal or volumetric measurement was used
(areal, 11 of 46 subjects; volumetric, 10 of 46 subjects).
Although the areal and volumetric lumbar spine BMD
measurements were significantly correlated, as ex-
pected, there were important differences in the classi-
fication of diminished BMD in individual survivors.
These incongruent findings are significant for individ-
ual survivors because the monitoring of, and interven-
tions for, diminished BMD are based on z-score
findings. Using thresholds defined by the WHO for
osteopenia/osteoporosis, 30% of the subjects with os-
teopenia identified by volumetric z-score had a normal
areal z-score and were of average height. Conversely,
36% of the subjects with osteopenia identified by areal
z-score had a normal volumetric z-score; these
survivors were small for their age, and their higher vol-
umetric scores likely reflects correction of an underes-Table 3. Factors Associated with Volumetric BMD in Multi-
variate Analysis
Covariate Coefficient* 95% CI P Value
Female 20.765 21.375 to 20.155 .015
Age 20.070 20.116 to 20.024 .004
CNS irradiation 20.954 21.710 to 20.200 .015
FMI (kg/m2) 0.099 0.006 to 0.193 .037
R2 5 0.345
BMD indicates bone mineral density; FMI, fat mass index; FFMI, fat-free
mass index.
*Multiple linear regression was performed using volumetric BMD
z-score as the response variable and considering the following covari-
ates: age, sex, Tanner stage, age at BMT, years since BMT, type of
BMT, TBI based preparative regimen, CNS irradiation, history of
cGVHD, abnormal endocrine function, FFMI, FMI, and controlling for
cumulative steroid dose. Forward selection with a 5 0.1 was used to
determine the final model, and a 5 0.05 was used for significance.timated areal measurement. We found that 88% of
survivors who were below the 3rd percentile for height
had higher BMD z-scores with volumetric measure-
ment, providing further evidence that DEXA-derived
volumetric measures may correct for underestimation
of BMD in this population.
Our findings suggest that DEXA-derived volumet-
ric calculation of lumbar BMD is the most appropriate
method for BMT survivors who are small for their age.
Although the most appropriate measure to use in
diagnosis and subsequent treatment of osteopenia/
osteoporosis in survivors who are not small for their
age is not determined by the results of this study, we
recommend standardizing a volumetric measurement
for all childhood BMT survivors.BMDAssociations
In addition to measurement issues, the understand-
ing of mechanisms necessary to develop and maintain
optimal BMD in cancer survivors is evolving. The im-
portance of understanding the full spectrum of factors
that contribute to BMD is critical in evaluating causes
and developing interventions for diminished BMD in
BMT survivors. Body composition (fat mass and fat-
free mass) is associated with BMD in healthy popula-
tions, but anevaluationof theseassociations in childhood
BMT survivors has not yet been reported [13].
In this study, we found that FMI was associated
with higher volumetric z-scores. Fat mass has been as-
sociated with increased BMD in obese children and
adolescents and is thought to result from the increased
mechanical loading placed on the bones [17]. Another
possible explanation is elevated leptin levels associated
with obesity. Leptin stimulates chondrocytes and is
hypothesized to contribute to BMD in obese individ-
uals [17,18].
The positive effects of fatmass onBMDare accom-
panied by health risks associated with obesity, such as
diabetes and heart disease. Therefore, it would be inap-
propriate to suggest increasing fatmass beyond healthy
recommendations in survivors when other means of
maintaining and increasing BMD exist. Studies in
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that increases lean mass and fitness can maintain or
increase BMD, despite the fact that exercise also de-
creases body fat [19]. Our findings suggest that exercise
interventions designed to increase BMD in childhood
BMT survivors should recognize the important rela-
tionships among bone, muscle, and fat and capitalize
on interventions that will have a positive impact on
overall health.
Our analysis identified other treatment and demo-
graphic associations as well. Our findings confirm pre-
vious studies that found an association between CNS
irradiation and decreased BMD [8,20,21]. There are
several explanations for this finding. In 75% of the
survivors who received CNS irradiation, the lumbar
spine was included in the field; thus, a radiation-
induced drop in chondrocytes might have contributed
to the association with lower lumbar BMD [22]. The
doses and sites of CNS irradiation varied, and the sam-
ple was too small to allow examination of site and dose
associations, but this would be important to consider
in future studies.
In other CNS-irradiated patient populations, anti-
epileptic agents and physical disability have been asso-
ciated with diminished BMD [23], which also might
help explain the relationship identified in the present
study. Although no survivor in our study was currently
receiving an antiepileptic agent, some might have had
previous exposure to these agents. Finally, 2 of our sur-
vivors who received CNS irradiation were treated for
CNS tumors, which require higher doses of radiation
in addition to surgical interventions. Both of these sur-
vivors had significant ataxia that limited their physical
activity, especially high-impact activities, which are
known to be important for improving and maintaining
BMD.
In addition, CNS irradiation may be associated
with pituitary dysfunction, resulting in thyroid, go-
nadal, and/or growth hormone deficiency, all of which
can negatively affect BMD. Even though all of the
survivors with diagnosed hormone deficiency were
receiving hormone replacement therapy, there might
have been more subtle, untreated abnormalities in the
CNS-irradiated group. For example, subnormal
androgen levels have been identified in female BMT
survivors, and testosterone replacement has been
shown to improve BMD in women with hypogonadal
functioning because of hypopituitarism [24]. In the
present study, endocrine function and replacement
data were based solely on medical record review and
subject reports; levels were not measured. Future stud-
ies should consider further evaluation of endocrine
function and the impact of current hormone replace-
ment strategies on BMD.
We also found that older age at the time of testing
was associated with lower volumetric z-scores. The
lower volumetric z-scores in older survivors empha-sizes the need for screening and intervention in child-
hood survivors to achieve and maintain optimal peak
bone mass.
Female BMT survivors were found to have lower
volumetric z-scores. In healthy older females, osteopo-
rosis andosteopenia aremajor health concerns; compro-
mised BMD after BMT will make this an even greater
concern for female survivors. Diminished BMD in
female childhood BMT survivors has previously been
reported and attributed to gonadal dysfunction [1]. As
noted earlier, endocrine abnormalities not readily
diagnosed in female survivors, including androgen
deficiency, might contribute to the negative association
between female sex and volumetric BMD found in our
study. Six of the 8 (75%) females with abnormal endo-
crine functionwere receiving gonadal hormone replace-
ment therapy at the time of testing. Research is needed
to identify the optimal hormone replace strategies in
female BMT survivors.
Steroid treatment has been implicated in dimin-
ished BMD before and after childhood BMT [7,25].
However, we found that cumulative steroid dose,
including therapies before BMT through the
resolution of cGVHD, was not associated with lower
volumetric z-scores in either univariate analysis (b 5
0.000; P 5 .150) or multivariate analysis (b 5 0.000;
P 5 .073). A possible explanation for this finding
includes the fact that the previous studies were
conducted in childhood BMT survivors closer to the
time of treatment (up to 12 months post-BMT) [7].
Evidence exists suggesting that the effects of steroids
on BMD are reversible, and that BMD increases after
discontinuation of steroid therapy [26]. In our study,
the mean time post-BMT was 8 years (range, 2-22
years), and no subject was actively taking steroids.
Our findings suggest that the diminished BMD associ-
ated with steroid treatment is time-limited and might
recover over time in childhood BMT survivors.Therapeutic Considerations
Treatment of diminished BMD after childhood
cancer has not been well studied. Most studies have
had small sample sizes, included only hematologic
malignancies, and used bisphosphonates [27-30].
Biphosphonate therapy also has been used in the
treatment and prevention of diminished BMD in
adults undergoing BMT [31-33]. Although these
previous studies have shown that bisphosphonates are
well tolerated and improve BMD in these populations,
more information is needed on which to base
treatment recommendations. Certainly treatment of
any underlying condition, such as an endocrinopathy,
is recommended in survivors with diminished BMD.
Treatment with calcium, vitamin D, and exercise has
been studied in healthy pediatric populations and has
shown varying degrees of effectiveness [33-36]. An
1456 Biol Blood Marrow Transplant 16:1451-1457, 2010K. Ruble et al.ongoing, longitudinal study of these interventions in
childhood ALL survivors might validate the
effectiveness of such a treatment approach in this
population [37].
In conclusion, maintenance of appropriate BMD is
multifactorial, and the etiology of diminished BMD
may change over time in childhood BMT survivors.
Our findings confirm that childhood BMT survivors
are at risk for abnormal BMD, primarily osteopenia.
Osteopenia in younger populations has been shown
to predict future osteoporosis and fractures [38]. Early
detection of diminished BMD will allow for appropri-
ate interventions and may prevent future disability.
We recommend the use of volumetric measure-
ments of BMD in survivors who are small for their
age. Further research comparing other methods, in-
cluding QCT, is needed to confirm that DEXA-
derived volumetric measures are most appropriate
for all BMT survivors.
The FMI value was found to have a positive
association with BMD. Interventions that increase
fat-free mass and improve overall fitness may help
maintain BMD in survivors who are obese. The signif-
icance of fat mass is an important addition to the
understanding of BMD outcomes in BMT survivors
and may help guide interventions in individual pa-
tients. Additional risk factors for diminished BMD
identified in this study include treatment with CNS
irradiation and female sex. Further research is needed
to elucidate the underlying mechanisms for these asso-
ciations, and these studies should include the evalua-
tion of possible endocrine etiologies and interventions.ACKNOWLEDGMENTS
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